Long before anyone called it an “exercise mimetic,” AICAR was just a molecule your own cells already make. It sits partway along the pathway that builds purines from scratch, one step in the quiet chemistry that keeps DNA and ATP supplied. That ordinary origin is easy to lose behind the headlines, so the history is worth telling in order.
What is AICAR (acadesine)?
AICAR is short for 5-aminoimidazole-4-carboxamide ribonucleotide. The related nucleoside form is often written AICA riboside, and the compound also carries the drug-development name acadesine (CAS 2627-69-2). Despite the way it is sometimes grouped with research peptides online, it is not a peptide at all. It is a small-molecule nucleoside analogue.
Its interest comes from what happens once it enters a cell. AICAR is taken up and phosphorylated to a monophosphate called ZMP, a molecule that closely resembles AMP, the signal a cell releases when its energy is running low. ZMP mimics AMP well enough to switch on AMP-activated protein kinase, or AMPK, the enzyme that acts as a master fuel gauge for the cell. That single trick, a compound that raises the AMPK signal without actually draining the cell’s ATP, is the thread running through every chapter below.
1995: a tool for studying AMPK
The modern research story starts in Scotland. In 1995, J. M. Corton, J. G. Gillespie, S. A. Hawley and D. G. Hardie at the University of Dundee published a paper in the European Journal of Biochemistry asking whether AICAR could serve as “a specific method for activating AMP-activated protein kinase in intact cells.” The question mark in that title was deliberate. They had found that AICAR let them turn AMPK on inside living cells without the crude tricks used earlier, such as heat shock or fructose loading, which disturbed the cell in other ways.
That paper turned AICAR into a standard laboratory reagent. For years afterward it was mostly a bench tool, the compound you reached for when you wanted to see what AMPK did in muscle, liver or fat tissue. The Dundee group’s caution also aged well: later work confirmed that ZMP has effects beyond AMPK, which is why careful studies still treat AICAR results with a degree of skepticism.
Acadesine: the clinical years
In parallel, the same molecule was being developed as a drug under the name acadesine. Here the idea was different. Researchers framed it as an “adenosine-regulating agent,” a compound that might boost local adenosine in tissues starved of oxygen. That thinking led to trials in cardiac surgery, where the concern is protecting the heart during coronary artery bypass grafting.
The cardiac program was large. A 2006 pooled analysis drew together thousands of bypass patients, and the surrounding effort was serious enough to help launch a dedicated biopharmaceutical company. Acadesine later resurfaced in oncology: a multicenter phase I/II study, reported around 2013, examined it in patients with relapsed or refractory chronic lymphocytic leukemia, on the rationale that ZMP could push those particular cells toward apoptosis. Neither the cardiac nor the leukemia work ended in regulatory approval. That failed-drug history is a real and often overlooked part of AICAR’s story.
2008: the “exercise mimetic” headline
The moment that made AICAR famous outside biochemistry came in 2008. Vihang Narkar, Ronald Evans and colleagues at the Salk Institute published a paper in Cell titled “AMPK and PPARδ Agonists Are Exercise Mimetics.” Working in mice, they reported that AICAR alone increased treadmill running endurance in otherwise sedentary animals, and that pairing it with the PPARδ agonist GW501516 shifted muscle toward a more oxidative, fatigue-resistant profile, the kind of change endurance training normally produces.
The press ran with “exercise in a pill.” The science was narrower than the slogan: these were rodent studies, using sustained dosing, measuring one lab endpoint. But the finding was striking enough to reframe how a whole field thought about the AMPK–PPARδ axis, and it is the reason “AICAR exercise mimetic” is still the phrase most people search for.
Prohibition and present standing
The endurance data had a swift regulatory echo. The World Anti-Doping Agency added both AICAR and GW501516 to its Prohibited List in 2009, and they remain banned in sport. That status is itself a piece of history: it reflects how seriously the mouse results were taken, even without human efficacy data behind them.
So the honest summary is a molecule pulled in three directions. AICAR is a genuine natural metabolite and a well-worn AMPK research tool, a drug candidate that never crossed the approval line, and a preclinical curiosity whose reputation outran its evidence. Its science is real; its maturity as anything more than a research compound is not.
Research use only. AICAR is supplied by Vero Labs strictly as a research compound for laboratory investigation. It is not intended for human or animal use, and nothing above is medical, dosing or performance advice. Every batch is independently third-party lab-tested for identity and purity, with a published certificate of analysis (COA) available for each lot.